Several large DLBCL patient cohorts exist including CHOP and/or R-CHOP response data and molecular profiling [38–40]; however, to date, there are no large-scale studies with comprehensive data on cisplatin-based therapy response and molecular profiling data available. Here, DDIT3 is linked to diffuse large B-cell lymphoma.